Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
Clinical and Translational Oncology · 2023
DOI: 10.1007/s12094-022-03070-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2023. Verfasst von Ioanna Ploumaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Athens.
Abstract (Originalsprache)
Due to their key role in the pathogenesis of cancer through the regulation of apoptosis, the B-cell leukemia/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer therapy for the past decades. Throughout the years, many Bcl-2 family inhibitors have been developed, with Venetoclax being now successfully used in treating hematological malignancies. Although their effectiveness in the treatment of solid tumors is yet to be established, some preclinical evidence indicates their possible clinical application. This review aims to summarize current data from completed clinical trials that used Bcl-2 protein family inhibitors as monotherapy or in combination with other agents for the treatment of solid malignancies. We managed to include clinical trials of various phases which analyze the pharmacokinetics and pharmacodynamics of the drugs, as well as the effectiveness and adverse effects. Active and recruiting clinical trials are also briefly presented and future prospects and challenges are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece. giannhskmpr@gmail.com.
Förderung
- University of Athens
Zitieren
APA
Ploumaki, I., Triantafyllou, E., Koumprentziotis, I. A., Karampinos, K., Drougkas, K., Karavolias, I., Trontzas, I., & Kotteas, E. A. (2023). Bcl-2 pathway inhibition in solid tumors: a review of clinical trials. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-022-03070-9
Vancouver
Ploumaki I, Triantafyllou E, Koumprentziotis IA, Karampinos K, Drougkas K, Karavolias I, et al. Bcl-2 pathway inhibition in solid tumors: a review of clinical trials. Clinical and Translational Oncology. 2023. doi:10.1007/s12094-022-03070-9
BibTeX
@article{Ploumaki2023,
author = {Ploumaki, Ioanna and Triantafyllou, Efthymios and Koumprentziotis, Ioannis-Alexios and Karampinos, Konstantinos and Drougkas, Konstantinos and Karavolias, Ioannis and Trontzas, Ioannis and Kotteas, Elias A},
title = {Bcl-2 pathway inhibition in solid tumors: a review of clinical trials},
journal = {Clinical and Translational Oncology},
year = {2023},
doi = {10.1007/s12094-022-03070-9}
}
EUVIMED